These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11185673)

  • 1. Crossover trials should not be used to test one treatment against another treatment with a totally different chemical class/mode of action.
    Cleophas TJ
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1503-8. PubMed ID: 11185673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An alternative analysis for crossover studies that accounts for between-group disparities in drug response.
    Cleophas TJ
    Eur J Clin Chem Clin Biochem; 1997 Oct; 35(10):775-9. PubMed ID: 9368796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design considerations in crossover trials with a single interim analysis and serial patient entry.
    Cook RJ; Willan AR
    Biometrics; 1996 Jun; 52(2):732-9. PubMed ID: 8672709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An alternative analysis for crossover studies that accounts for between-group disparities in drug response.
    Cleophas TJ
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):504-8. PubMed ID: 9401831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials.
    Rosenfeldt FL; Haas SJ; Krum H; Hadj A; Ng K; Leong JY; Watts GF
    J Hum Hypertens; 2007 Apr; 21(4):297-306. PubMed ID: 17287847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of extensions of bivariate rank sum statistics to the crossover design to compare two treatments through four sequence groups.
    Kawaguchi A; Koch GG; Ramaswamy R
    Biometrics; 2009 Sep; 65(3):979-88. PubMed ID: 19173698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CrossOver: an algorithm for the construction of efficient cross-over designs.
    John JA; Russell KG; Whitaker D
    Stat Med; 2004 Sep; 23(17):2645-58. PubMed ID: 15316948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crossover studies with continuous variables: power analysis.
    Cleophas TJ; Zwinderman AH
    Am J Ther; 2002; 9(1):69-73. PubMed ID: 11782821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies.
    Zucker DR; Ruthazer R; Schmid CH; Feuer JM; Fischer PA; Kieval RI; Mogavero N; Rapoport RJ; Selker HP; Stotsky SA; Winston E; Goldenberg DL
    J Rheumatol; 2006 Oct; 33(10):2069-77. PubMed ID: 17014022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cluster-crossover design: a method for limiting clusters level effect in community-intervention studies.
    Parienti JJ; Kuss O
    Contemp Clin Trials; 2007 May; 28(3):316-23. PubMed ID: 17110172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the maximum test statistic in the two-period crossover clinical trial.
    Willan AR
    Biometrics; 1988 Mar; 44(1):211-8. PubMed ID: 3358989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-period crossover designs for two treatments.
    Ebbutt AF
    Biometrics; 1984 Mar; 40(1):219-24. PubMed ID: 6733230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Translation and validation of a French version of the Young Mania Rating Scale (YMRS)].
    Favre S; Aubry JM; Gex-Fabry M; Ragama-Pardos E; McQuillan A; Bertschy G
    Encephale; 2003; 29(6):499-505. PubMed ID: 15029084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials: relevance of correlation between treatment modalities.
    Cleophas TJ
    Int J Clin Pharmacol Ther; 1995 Dec; 33(12):670-5. PubMed ID: 8963485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of a crossover clinical trial by permutation methods.
    Good P; Xie F
    Contemp Clin Trials; 2008 Jul; 29(4):565-8. PubMed ID: 18356118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The importance of equivalence trials in showing the usefulness of treatments].
    Hermens ML; van Hout HP; Terluin B; Adèr HJ; de Haan M
    Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2162-6. PubMed ID: 14626832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials.
    Lathyris DN; Trikalinos TA; Ioannidis JP
    Int J Epidemiol; 2007 Apr; 36(2):422-30. PubMed ID: 17301102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S; Robbins J; West CR; Nemeth MA
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.